Compare Adaptive Biotechnologies Corp (ADPT) vs iShares iBoxx $ High Yield Corporate Bond ETF (HYG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs iShares iBoxx $ High Yield Corporate Bond ETF — how do they compare? Adaptive Biotechnologies Corp trades at $24.96 (market cap $4.04B), while iShares iBoxx $ High Yield Corporate Bond ETF trades at $79.62. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, iShares iBoxx $ High Yield Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| ADPT | HYG | |
|---|---|---|
Market Cap | $4.04B | — |
Sector | Health | Fixed Income |
52-Week High | $25.45 | $81.32 |
52-Week Low | $12.30 | $78.72 |
Enterprise Value | $4.10B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $25.45, up 2.09% today, near its 52-week high. The stock shows bullish technical signals with support at $25 and resistance at $26. Revenue growth accelerated to $277M in 2025, though net losses persist. Recent news highlights a strategic separation of its MRD and Immune Medicine businesses, aiming to unlock value.
Outlook is cautiously optimistic with 65% analyst buy ratings and a $25.50 price target. Key opportunities include MRD segment profitability and separation benefits, while risks involve sustained losses, competitive pressures, and execution challenges in the business split.
HYG, the iShares iBoxx $ High Yield Corporate Bond ETF, trades at $79.615, up 0.17% on the day. Technical indicators show a bearish trend with key support at $79 and resistance at $80. Recent news highlights bond market volatility amid inflation concerns and rising oil prices, while the ETF faces criticism for underperformance versus peers.
The outlook for HYG is cautious due to bearish technicals and macroeconomic headwinds like potential Fed rate hikes. Risks include high-yield credit exposure and inflation sensitivity, but the ETF's 6.5% dividend yield may attract income-focused investors amid broader bond market inflows.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About iShares iBoxx $ High Yield Corporate Bond ETF
HYG is the world's largest high-yield bond ETF, tracking the Markit iBoxx USD Liquid High Yield Index. It provides liquid exposure to non-investment grade corporate debt, with 2026 top holdings including Cloud Software Group and Medline.
Read more on HYG →
